Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)

 Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)

Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)

Shots:

  • The P-I/III (NCT02792699) study involves assessing of ABP 798 vs Rituxan (rituximab, IV) in 311 patients in the ratio (1:1:1) with moderate-to-severe RA, evaluating safety, efficacy, and PK for 48 wks.
  • The study demonstrated in meeting 1EPs as AUC (area under the serum concentration–time curve) and Cmax (maximum serum concentration) with biosimiliarity in PK, efficacy, and safety
  • ABP 798 (rituximab, biosimilar) is a CD20-directed cytolytic mAb approved for RA, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) in the US and EU. In 2011, Amgen and Allergan globally collaborated to develop and commercialize three oncology biosimilar including ABP 798

Click here  to read full press release/ article | Ref: Amgen | Image:  Calispher

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post